The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The cGMP-4 facility will further strengthen the company's ability to serve global partners
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The new facility is scheduled to start operation in the first half of 2024
Subscribe To Our Newsletter & Stay Updated
